TAK
$17.83-0.28 (-1.55%)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare di...
Recent News
XOMA Royalty Q4 Earnings Call Highlights
XOMA Royalty (NASDAQ:XOMA) executives used the company’s 2025 financial results call to emphasize a year of portfolio expansion, rising royalty receipts, and what management described as progress toward a business model in which recurring royalties can cover core operating costs. Management highlig
Halozyme Therapeutics Touts $1.8B Revenue Outlook, ENHANZE Royalties and New Hypercon Deals at Conference
Halozyme Therapeutics (NASDAQ:HALO) executives highlighted the company’s royalty-driven growth outlook and expanding subcutaneous drug delivery platform during remarks at the Citizens Life Sciences Conference, pointing to strong momentum from key partnered products, new collaboration activity, and r
Alkermes CEO Pops Calls 2026 a “Really Exciting Year” as Orexin Agonists Near Narcolepsy Launch
Alkermes (NASDAQ:ALKS) CEO Richard Pops said the company is entering what he described as a “really exciting year” as the orexin agonist field moves closer to commercialization in narcolepsy, with broader ambitions in other disorders linked to wakefulness circuitry. Speaking in a conference panel di
KROS: Is the Discount Book Value a Value Trap?
Keros posts a 2025 revenue surge from Takeda licensing, but no product sales and volatile drivers leave investors weighing a discounted valuation against execution risk.
KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026
Keros lines up 2026 catalysts with rinvatercept at the core, including a Q2 DMD phase II start and ALS regulatory plans as execution shifts into focus.